{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:54:45Z","timestamp":1793105685264,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.phrs.2022.106405","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:51:12Z","timestamp":1661302272000},"page":"106405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"184","author":[{"given":"Zhe","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106405_bib1","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","author":"Sparks","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00296-017-3651-3","article-title":"Pain, social support and depressive symptoms in patients with rheumatoid arthritis: testing the stress-buffering hypothesis","volume":"37","author":"Brandstetter","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.phrs.2022.106405_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jbspin.2016.07.007","article-title":"Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review","volume":"83","author":"Minichiello","year":"2016","journal-title":"Jt. Bone Spine"},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cells10030647","article-title":"ACPA status correlates with differential immune profile in patients with rheumatoid arthritis","volume":"10","author":"Floudas","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101497","article-title":"The microbiome and rheumatoid arthritis","volume":"33","author":"Bergot","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106405_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.phrs.2022.106405_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib11","first-page":"242","article-title":"2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis","volume":"57","author":"Chinese Rheumatology Association","year":"2018","journal-title":"Chin. J. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib12","first-page":"5221","article-title":"Systematic review and meta-analysis of the efficacy and safety of Biqi capsule in rheumatoid arthritis patients","volume":"15","author":"Chen","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.phrs.2022.106405_bib14","doi-asserted-by":"crossref","first-page":"v22","DOI":"10.1093\/rheumatology\/kes115","article-title":"Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment","volume":"51","author":"Emery","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2022.106405_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.608703","article-title":"Clinical practice guideline for tripterygium glycosides\/Tripterygium wilfordii tablets in the treatment of rheumatoid arthritis","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106405_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114880","article-title":"A single-injection targeted metabolomics profiling method for determination of biomarkers to reflect tripterygium glycosides efficacy and toxicity","volume":"389","author":"Hu","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106405_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12906-016-1194-x","article-title":"Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00296-011-1841-y","article-title":"A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety","volume":"31","author":"Bao","year":"2011","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.phrs.2022.106405_bib19","first-page":"460","article-title":"Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus","volume":"6","author":"Patavino","year":"2001","journal-title":"Altern. Med. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s10067-015-3043-6","article-title":"Efficacy of tripterygium glycosides tablet in treating ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Li","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.ajkd.2013.02.374","article-title":"Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis","volume":"62","author":"Zhu","year":"2013","journal-title":"Am. J. Kidney Dis."},{"issue":"19","key":"10.1016\/j.phrs.2022.106405_bib22","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2169\/internalmedicine.49.3704","article-title":"Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy","volume":"49","author":"Chen","year":"2010","journal-title":"Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib23","doi-asserted-by":"crossref","first-page":"c223","DOI":"10.1159\/000208990","article-title":"Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis","volume":"111","author":"Xu","year":"2009","journal-title":"Nephron Clin. Pract."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib24","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/ptr.6996","article-title":"The effectiveness and safety of Tripterygium wilfordii glycosides combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of 40 randomized controlled trials","volume":"35","author":"Zheng","year":"2021","journal-title":"Phytother. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib25","first-page":"369","article-title":"A systematic review of tripterygium glycosides combined with leflunomide in treatment of rheumatoid arthritis","volume":"17","author":"Yin","year":"2022","journal-title":"World Chin. Med."},{"key":"10.1016\/j.phrs.2022.106405_bib26","article-title":"Tripterygium glycosides combined with leflunomide for rheumatoid arthritis: a systematic review and meta-analysis","volume":"2020","author":"Yang","year":"2020","journal-title":"Evid. Based Complement. Altern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib27","first-page":"791","article-title":"Meta-analysis of RCT studies on clinical efficacy of single administration of tripterygium glycosides tablets or combined administration with methotrexate against rheumatoid arthritis","volume":"45","author":"Chen","year":"2020","journal-title":"China J. Chin. Mater. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib28","first-page":"775","article-title":"Meta-analysis on safety of tripterygium glycosides tablets in treatment of rheumatoid arthritis","volume":"45","author":"Li","year":"2020","journal-title":"China J. Chin. Mater. Med."},{"issue":"12","key":"10.1016\/j.phrs.2022.106405_bib29","first-page":"128","article-title":"Systematic review and meta-analysis of the effect of tripterygium glycoside tablets on IL-23\/IL-17 axis related cytokines in the treatment of rheumatoid arthritis","volume":"17","author":"Wang","year":"2020","journal-title":"China Med. Her."},{"issue":"16","key":"10.1016\/j.phrs.2022.106405_bib30","first-page":"3542","article-title":"Meta-analysis of laboratory index of tripterygium glycosides tablets in treatment of rheumatoid arthritis","volume":"44","author":"Li","year":"2019","journal-title":"China J. Chin. Mater. Med."},{"issue":"16","key":"10.1016\/j.phrs.2022.106405_bib31","first-page":"3533","article-title":"Clinical symptoms effect of tripterygium glycosides tablets alone or combined with methotrexate in treatment of rheumatoid arthritis: a meta-analysis","volume":"44","author":"Wang","year":"2019","journal-title":"China J. Chin. Mater. Med."},{"issue":"15","key":"10.1016\/j.phrs.2022.106405_bib32","first-page":"3358","article-title":"Effect of tripterygium glycosides tablets in treating rheumatoid arthritis: a systematic review and meta-analysis","volume":"44","author":"Zhu","year":"2019","journal-title":"China J. Chin. Mater. Med."},{"issue":"35","key":"10.1016\/j.phrs.2022.106405_bib33","first-page":"5710","article-title":"Meta-analysis of tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis","volume":"23","author":"Yin","year":"2019","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"10.1016\/j.phrs.2022.106405_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2018.00356","article-title":"The effectiveness and safety of tripterygium wilfordii hook. F extracts in rheumatoid arthritis: a systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106405_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2017.01.004","article-title":"Treatment of rheumatoid arthritis with combination of methotrexate and Tripterygium wilfordii: A meta-analysis","volume":"171","author":"Wang","year":"2017","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib36","first-page":"677","article-title":"Tripterygium wilfordii extraction for treating rheumatoid arthritis: a meta-analysis","volume":"25","author":"Yang","year":"2016","journal-title":"Chin. J. Pharmacoepidemiol."},{"issue":"10","key":"10.1016\/j.phrs.2022.106405_bib37","first-page":"1032","article-title":"Tripterygium wilfordii extraction for treating rheumatoid arthritis: a meta-analysis","volume":"23","author":"Wang","year":"2014","journal-title":"Mod. J. Integr. Tradit. Chin. West. Med."},{"key":"10.1016\/j.phrs.2022.106405_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/410793","article-title":"Extracts of Tripterygium wilfordii hook F in the treatment of rheumatoid arthritis: a systemic review and meta-analysis of randomised controlled trials","volume":"2013","author":"Liu","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106405_bib39","article-title":"Herbal therapy for treating rheumatoid arthritis","volume":"16","author":"Cameron","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"20","key":"10.1016\/j.phrs.2022.106405_bib40","first-page":"2637","article-title":"Tripterygium wilfordii extract for treating rheumatoid arthritis: systematic review","volume":"34","author":"Jiang","year":"2009","journal-title":"China J. Chin. Mater. Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106405_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.phymed.2006.01.010","article-title":"A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis","volume":"13","author":"Canter","year":"2006","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2022.106405_bib45","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.phrs.2022.106405_bib46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.phrs.2022.106405_bib47","first-page":"23","article-title":"Efficacy of tripterygium wilfordii glycosides combined with methotrexate in the treatment of rheumatoid arthritis and its influence on bone repair indexes","volume":"13","author":"Wu","year":"2022","journal-title":"Chin. Manip. Rehabil. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib48","first-page":"2214","article-title":"Efficacy and mechanism of tripterygium wilfordii glycosides in the treatment of rheumatoid arthritis","volume":"44","author":"Lu","year":"2021","journal-title":"J. Chin. Med. Mater."},{"issue":"1","key":"10.1016\/j.phrs.2022.106405_bib49","first-page":"53","article-title":"Observation of the curative effect of tripterygium polyglycosides combined with leflunomide in the treatment of rheumatoid arthritis","volume":"37","author":"Wang","year":"2021","journal-title":"J. Pract. Tradit. Chin. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib50","first-page":"74","article-title":"Effect of tripterygium glycosides combined with leflunomide in the treatment of senile active rheumatoid arthritis","volume":"13","author":"Li","year":"2020","journal-title":"Chin. J. Clin. Ration. Drug Use"},{"issue":"2","key":"10.1016\/j.phrs.2022.106405_bib51","first-page":"339","article-title":"Efficacy and followed-up analysis of methotrexate combined with tripterygium glycosides tablets in treating elderly rheumatoid arthritis","volume":"15","author":"Zhu","year":"2020","journal-title":"World J. Integr. Tradit. West. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib52","first-page":"513","article-title":"Efficacy of methotrexate combined with tripterygium wilfordii glycosides on middle-aged and elderly patients with rheumatoid arthritis and its effect on metalloproteinase-3","volume":"39","author":"Lei","year":"2020","journal-title":"Gansu Med. J."},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib53","first-page":"90","article-title":"Effects of tripterygium wilfordii combined with methotrexate on bone metabolism and levels of inflammatory factors in serum in patients with rheumatoid arthritis","volume":"47","author":"Xun","year":"2020","journal-title":"Chin. J. Pract. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106405_bib54","first-page":"60","article-title":"Clinical evaluation of the combination regimen of Tripterygium wilfordii glycosides and leflunomide in the treatment of rheumatoid arthritis","volume":"27","author":"Gao","year":"2019","journal-title":"Chin. J. Trauma Disabil. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib55","first-page":"154","article-title":"Clinical effect of tripterygium wilfordii glycosides combined with leflunomide in the treatment of rheumatoid arthritis and its influence on serum inflammatory factors","volume":"17","author":"Jiang","year":"2019","journal-title":"Chin. Foreign Med. Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib56","first-page":"390","article-title":"Efficacy of tripterygium glycoside tablets combined with leflunomide in the treatment of rheumatoid arthritis and its influence on interleukin-6 and tumor necrosis factor-\u03b1 levels","volume":"47","author":"Sha","year":"2019","journal-title":"Clin. J. Med. Off."},{"issue":"51","key":"10.1016\/j.phrs.2022.106405_bib57","first-page":"129","article-title":"The short-term curative effect of tripterygium wilfordii glycosides combined with methotrexate in the treatment of rheumatoid arthritis and its influence on peripheral blood inflammatory factors","volume":"19","author":"Zhang","year":"2019","journal-title":"World Latest Med. Inf."},{"issue":"5","key":"10.1016\/j.phrs.2022.106405_bib58","first-page":"2","article-title":"Comparison of the effects of tripterygium wilfordii combined with methotrexate in the treatment of rheumatoid arthritis","volume":"17","author":"Wang","year":"2019","journal-title":"Guide of China Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106405_bib59","first-page":"13","article-title":"Clinical effect of methotrexate combined with Tripterygium wilfordii polyglycosides in the treatment of rheumatoid arthritis","volume":"12","author":"Liu","year":"2019","journal-title":"Chin. J. Clin. Ration. Drug Use"},{"issue":"7","key":"10.1016\/j.phrs.2022.106405_bib60","first-page":"145","article-title":"The effect of combined treatment of rheumatoid arthritis with tripterygium glycosides and methotrexate","volume":"19","author":"Chen","year":"2019","journal-title":"Pract. Clin. J. Integr. Tradit. Chin. West. Med."},{"issue":"7","key":"10.1016\/j.phrs.2022.106405_bib61","first-page":"71","article-title":"Effect of tripterygium glycosides tablets combined with methotrexate in treatment of rheumatoid arthritis","volume":"16","author":"Long","year":"2019","journal-title":"China Med. Her."},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib62","first-page":"107","article-title":"The clinical study of combined treatment of rheumatoid arthritis with tripterygium glycosides and methotrexate","volume":"17","author":"Li","year":"2019","journal-title":"J. China Prescr. Drug"},{"issue":"16","key":"10.1016\/j.phrs.2022.106405_bib63","first-page":"90","article-title":"Influence of tripterygium wilfordii polyglycoside tablets combined with methotrexate for erythrocyte sedimentation rate, C-reactive protein and rheumatoid factor in patients with rheumatoid arthritis","volume":"9","author":"Yu","year":"2019","journal-title":"China Med. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib64","first-page":"93","article-title":"The effect of tripterygium wilfordii glycosides combined with methotrexate on serum cytokine levels in elderly patients with rheumatoid arthritis","volume":"17","author":"Liu","year":"2019","journal-title":"J. China Prescr. Drug"},{"issue":"1","key":"10.1016\/j.phrs.2022.106405_bib65","first-page":"100","article-title":"Effect of Tripterygium polyglycosides combined with methotrexate on rheumatoid arthritis","volume":"38","author":"Yuan","year":"2018","journal-title":"Clin. Med."},{"issue":"10","key":"10.1016\/j.phrs.2022.106405_bib66","first-page":"117","article-title":"Clinical efficacy of tripterygium polyglycosides combined with methotrexate in the treatment of rheumatoid arthritis","volume":"45","author":"Wang","year":"2018","journal-title":"Chin. J. Pract. Med."},{"issue":"20","key":"10.1016\/j.phrs.2022.106405_bib67","first-page":"3909","article-title":"Curative efficacy of tripterygium glycosides combined with methotrexate in treatment of rheumatoid arthritis active stage and its effects on serum CD62p and CD41 Levels","volume":"18","author":"Chen","year":"2018","journal-title":"Prog. Mod. Biomed."},{"issue":"18","key":"10.1016\/j.phrs.2022.106405_bib68","first-page":"46","article-title":"Clinical efficacy of Tripterygium wilfordii polyglycoside tablets combined with methotrexate in the treatment of rheumatoid arthritis and its influence on inflammatory factors","volume":"8","author":"Zhuang","year":"2018","journal-title":"China Med. Pharm."},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib69","first-page":"1511","article-title":"Short term effect of tripterygium glycosides and methotrexate in treating rheumatoid arthritis and its influence on IL-1, IL-6, and TNF-\u03b1","volume":"29","author":"Gao","year":"2017","journal-title":"Med. J. West China"},{"issue":"4","key":"10.1016\/j.phrs.2022.106405_bib70","first-page":"385","article-title":"Research on the overall effect of methotrexate combined with multiglycosides of tripterygium wilfordiion the clinical intervention of rheumatoid arthritis","volume":"37","author":"Wang","year":"2017","journal-title":"Chin. J. Biochem. Pharm."},{"issue":"17","key":"10.1016\/j.phrs.2022.106405_bib71","first-page":"43","article-title":"Clinical study of Tripterygium wilfordii polyglycosides combined with methotrexate in the treatment of active rheumatoid arthritis","volume":"36","author":"Hou","year":"2017","journal-title":"Inn. Mong. J. Tradit. Chin. Med."},{"issue":"12","key":"10.1016\/j.phrs.2022.106405_bib72","first-page":"52","article-title":"Clinical analysis of tripterygium glycosides combined with methotrexate tablets in the treatment of rheumatoid arthritis","volume":"9","author":"Wang","year":"2016","journal-title":"Chin. J. Clin. Ration. Drug Use"},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib73","first-page":"96","article-title":"Efficacy and safety of tripterygium wilfordii combined with methotrexate in the treatment of rheumatoid arthritis","volume":"24","author":"Lu","year":"2016","journal-title":"China Med. Eng."},{"issue":"10","key":"10.1016\/j.phrs.2022.106405_bib74","first-page":"880","article-title":"Clinical efficacy of tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis","volume":"32","author":"Bi","year":"2016","journal-title":"Chin. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106405_bib75","first-page":"136","article-title":"The clinical effect of methotrexate plus tripterygium wilfordii polyglycosides in the treatment of rheumatoid arthritis","volume":"36","author":"Liao","year":"2016","journal-title":"Chin. J. Biochem. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2022.106405_bib76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2013-204807","article-title":"Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial","volume":"74","author":"Lv","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"17","key":"10.1016\/j.phrs.2022.106405_bib77","first-page":"2598","article-title":"Clinical efficacy of methotrexate combined with tripterygium glycosides in the treatment of rheumatoid arthritis","volume":"21","author":"Wang","year":"2015","journal-title":"Int. Med. Health Guid. News"},{"issue":"16","key":"10.1016\/j.phrs.2022.106405_bib78","first-page":"152","article-title":"The therapeutic effect of tripterygium wilfordii glycosides combined with leflunomide in the treatment of 48 cases of senile active rheumatoid arthritis","volume":"20","author":"Long","year":"2014","journal-title":"Contemp. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib79","first-page":"659","article-title":"Study on efficacy and safety of combined methotrexate with Tripterygium wilfordii polyglycoside tablets in treatment of patients with rheumatoid arthritis","volume":"12","author":"Feng","year":"2013","journal-title":"J. Clin. Exp. Med."},{"issue":"17","key":"10.1016\/j.phrs.2022.106405_bib80","first-page":"300","article-title":"Clinical observation on treatment of rheumatoid arthritis with tripterygium wilfordii polyglycoside combined with methotrexate","volume":"19","author":"Yang","year":"2013","journal-title":"Chin. J. Exp. Tradit. Med. Formula"},{"issue":"11","key":"10.1016\/j.phrs.2022.106405_bib81","first-page":"1678","article-title":"The therapeutic effect of tripterygium wilfordii combined with methotrexate on rheumatoid arthritis","volume":"20","author":"Wang","year":"2013","journal-title":"Chin. J. Prim. Med. Pharm."},{"issue":"S2","key":"10.1016\/j.phrs.2022.106405_bib82","first-page":"602","article-title":"Clinical observation on the treatment of rheumatoid arthritis with tripterygium glycosides and methotrexate","volume":"14","author":"Zhang","year":"2012","journal-title":"Chin. J. Med. Guide"},{"issue":"12","key":"10.1016\/j.phrs.2022.106405_bib83","first-page":"2194","article-title":"Efficacy of tripterygium glycosides combined with leflunomide in the treatment of senile active rheumatoid arthritis","volume":"31","author":"Zhang","year":"2011","journal-title":"Chin. J. Gerontol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106405_bib84","first-page":"7","article-title":"Clinical evaluation of tripterygium wilfordii polyglycosidium combined with methotrexate in treating rheumatoid arthritis and its effect on TNF-\u0251 and IL-6","volume":"17","author":"Tan","year":"2010","journal-title":"Chin. J. Inf. TCM"},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3 Suppl. 59","key":"10.1016\/j.phrs.2022.106405_bib86","first-page":"S18","article-title":"The assessment of disease activity in rheumatoid arthritis","volume":"28","author":"Smolen","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106405_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.22552","article-title":"A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response","volume":"57","author":"American College of Rheumatology Committee to Reevaluate Improvement Criteria","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.phrs.2022.106405_bib88","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106405_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.phrs.2022.106405_bib90","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J. Rheumatol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:40:10Z","timestamp":1760913610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822003504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":90,"alternative-id":["S1043661822003504"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106405","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106405"}}